"HIV Integrase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA.
| Descriptor ID |
D019428
|
| MeSH Number(s) |
D27.505.519.389.375.400 D27.505.954.122.388.077.088.314
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Integrase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Integrase Inhibitors".
This graph shows the total number of publications written about "HIV Integrase Inhibitors" by people in this website by year, and whether "HIV Integrase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 2 | 0 | 2 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 3 | 4 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Integrase Inhibitors" by people in Profiles.
-
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial. Lancet HIV. 2025 Mar; 12(3):e201-e213.
-
Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics. AIDS. 2024 Dec 01; 38(15):2073-2085.
-
Influence of age and co-medication on dolutegravir glucuronidation in paediatric patients. Br J Clin Pharmacol. 2024 Nov; 90(11):2947-2952.
-
Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
-
Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
-
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 04; 10(4):e254-e265.
-
Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study. Molecules. 2022 Dec 19; 27(24).
-
Compelling evidence for unconditional shift to dolutegravir. Lancet HIV. 2022 08; 9(8):e523-e524.
-
Dolutegravir for children with HIV-associated tuberculosis. Lancet HIV. 2022 09; 9(9):e599-e600.
-
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children. N Engl J Med. 2021 12 30; 385(27):2531-2543.